AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | After market close | $700.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 1, 2026 | After market close | – | – | – |
Press releases
Announcements 20/20 Biolabs filed with the SEC
Investor Webinar NASDAQ: AIDX September 2, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED ON AUGUST 17, 2026
Results of operations · EX-99.1 to Form 8-K
OneTest Advantages Over ctDNA — Our "Straight A's" • Accuracy for Earlier Stage Cancers • Affordability • Acceleration over Time • Aggregates Data from Multiple Sources • Access at Home & Workplaces • AI Compatible for Consumers & Clinicians
Regulation FD disclosure · EX-99.1 to Form 8-K
OneTest Advantages Over ctDNA — Our "Straight A's" • Accuracy for Earlier Stage Cancers • Affordability • Acceleration over Time • Aggregates Data from Multiple Sources • Access at Home & Workplaces • AI Compatible for Consumers & Clinicians
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED ON MAY 20, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED ON MARCH 31, 2026
Results of operations · EX-99.1 to Form 8-K